News

If successful, oral cladribine will be the first oral therapy for multiple sclerosis with the convenience of short courses of therapy with intermittent administration. The study will provide

Prolysis is aiming to develop new antibacterial compounds to tackle life-threatening, drug-resistant infections caused by staphylococci, including MRSA. MRSA is fast becoming untreatable with the currently available antibiotics.

In Europe, orphan drug designation provides market exclusivity for up to 10 years to companies that develop drugs for underserved patient populations. Prochymal has already been granted both

Recent research by Professor Bloom and his team identified the role played by gut hormones in appetite control. These hormones are released when a person eats, acting as

The studies were conducted by the University of Texas MD Anderson Cancer Center and the University of Texas Southwestern Medical Center. Two tumor-suppressing genes given intravenously reduced cancer

Cerezyme, an enzyme replacement therapy, is the standard of care for patients with type 1 Gaucher disease. Patients with Gaucher disease are at increased risk for developing bone

Since 2002, Novo Nordisk has increased its focus on pharmaceuticals based on therapeutic proteins, and the company's pipeline of protein-based pharmaceuticals within diabetes, haemostasis, growth disorders and other

The study indicated that six months of treatment with Tracleer showed a significant reduction in pulmonary vascular resistance, a primary endpoint of the study. Patients also showed a

Orphan drug designation is a special status for diseases or conditions affecting fewer than 200,000 patients in the US. “Both LX211 and LX201 have the potential of establishing